Here, we present the initial instance of a non‐small cell lung cancer (NSCLC) patient with an EGFR mutation who also harbored both NTRK1 and ZRSR2 mutations, which are recognized as significant factors in the development of primary resistance to Osimertinib through further validation. Here, EGFR is linked to lung cancer.